DIABETICS offered pain-free future with NEMAURA'S new way of delivering insulin

DIABETICS offered pain-free future with NEMAURA'S new way of delivering insulin

- in Business
58
0

Nemaura devicesPR

Nemaura have invented a new soft touch device to deliver insulin to diabetics

Latest tests have shown patients didn’t feel or barely felt its super shallow micro-needle Memspatch IMD. 

Once loaded with a pre-configured dose they place it flat against their arm or thigh for a few seconds, considered to be a calming action in itself, and job done.

If approvals go ahead as planned Nemaura expects it to be available later next year in a market where the effects of people not taking their medicines properly, because of complications or side effects, costs the NHS £1billion a year.

Finding better ways of delivering drugs and administering them more conveniently through the skin, using devices with diagnostic patches and mobile apps for example, have become the core focus of the company’s work.

Now chief executive Dr Faz Chowdhury, who founded the business in 2005, finds the medical world increasingly coming round to his way of thinking.

In the coming decade the global skin drug delivery market is expected to grow over 12 per cent and be worth £75 billion plus with trans-dermal pain-free drugs a top trend.

“Needle phobia is a major barrier to health,” Chowdhury explains. “Over 50 per cent of adults with Type 2 Diabetes delay taking insulin because of that and 90 per cent feel fear when doing it.

Nemaura  labPR

Patients barely felt or did not feel the devices micro needle at all


Needle phobia is a major barrier to health

Dr Faz Chowdhury


“Our Memspatch IMD requires little training, making doing it yourself much easier and less stressful.

“Our goal is simple: reduce side-effects and increase compliance.”

The diabetes innovation is one in a long pipeline for the developer which has sealed a global licensing deal for an Alzheimer’s skin patch too.

This aims to transform how sufferers take what are often complex cocktails of drugs and ease the burden of responsibilities on carers.

Loughborough UniversityPR

The company has a five lab suite in the Advanced Technology and Innovation Centre

“Patients can easily forget in a difficult situation like this or have trouble swallowing, this ensures they get what they need,” says Chowdhury who sees the potential for other chronic conditions as well such as migraine.

Nemaura has also tackled the entrenched problems associated with vaccines’ liquid formulations, which normally require being transported and stored at low temperatures, something that creates significant logistical and cost problems for medical teams in remote areas.

But the company’s expertise in nano drug delivery has turned these liquids into microscopic particles that don’t require refrigeration and can be administered by non-skilled workers, creating another possible game-changer for disease prevention in the developing world.

Medical innovation is one of the longest games however, and hugely expensive, with devices and drugs, multiple patents, trials and approvals sometimes taking a decade or more to develop.

So far Chowdhury, who alone has 50 inventions under his belt, has raised £25 million from private investment and £2 million from enterprise funding for Nemaura.

Licence and royalty revenues, currently around £5 million, are forecast to rise to over £10 million by 2019.

“But we are ambitious and have a £100 million target for 2025 for the 22 drugs we have in development,” says Chowdhury whose sees the firm’s closer involvement in the commercial roll-out of Memspatch IMD creating better margins.

NemauraPR

Dr Faz Chowdhury wants to use patches and devices to deliver medicine conveniently though the skin

More expansion on the jobs front too is planned now the company has a five lab suite in Loughborough University’s Advanced Technology and Innovation Centre with staff numbers to increase to 200 by 2025.

“There’s no doubt about it, being part of the life sciences cluster in the East Midlands with access to expertise on our doorstep has helped us grow to be a company with global impact,” adds Chowdhury. “Nemaura is at a tipping point and here we have everything we need to advance to the next level.”

Nemaura.co.uk

Nemaura is a finalist in the best innovation category in the life sciences industry leading Medilink UK Awards to be announced next April www.medilinkuk.com

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like

The New Washington: ‘The New Washington’: Senator Kirsten Gillibrand

Senator Kirsten Gillibrand, Democrat of New York.